aibio8158 China Regenerative Medicine International Limited
China Regenerative Medicine International (8158) news
China Regenerative Medicine International Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 8158, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest China Regenerative Medicine International news
We have not published a story on China Regenerative Medicine International yet. When there is news, it will appear here.
Questions about China Regenerative Medicine International
What is the ticker symbol of China Regenerative Medicine International?
China Regenerative Medicine International Limited trades under the ticker 8158 on HKEX.
Where is China Regenerative Medicine International listed?
China Regenerative Medicine International Limited is listed on HKEX.
Which country or territory is China Regenerative Medicine International listed under?
Our directory records China Regenerative Medicine International Limited under Hong Kong.
What does China Regenerative Medicine International do?
Our directory classifies China Regenerative Medicine International Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of China Regenerative Medicine International?
The ISIN recorded for China Regenerative Medicine International Limited is KYG2129W1380.
Does aibio.space cover China Regenerative Medicine International?
aibio.space lists China Regenerative Medicine International Limited among 2,820 public biotech companies and publishes its news here as stories appear.
Which companies are similar to China Regenerative Medicine International?
Companies in our directory listed in the same country and business area as China Regenerative Medicine International: Regencell Bioscience Holdings, Beijing Tong Ren Tang Chinese Medicine Co., Grand Pharmaceutical Group, HUTCHMED (China), Tianda Pharmaceuticals, InSilico Medicine Cayman TopCo.
Investor discussion: China Regenerative Medicine International
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Share or debt issue: PROPOSAL FOR (1) GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES; (2) EXTENSION OF GENERAL MANDATE TO ISSUE SHARES; (3) RE-ELECTION OF THE RETIRING DIRECTORS; (4) PROPOSED ADOPTION OF NEW MEMORANDUM AND ARTICLES OF ASSOCIATION; AND (5) NOTICE OF ANNUAL GENERAL MEETING. Source
- Mergers
Transaction under the Listing Rules: (1) MAJOR TRANSACTIONS IN RELATION TO THE OUTSTANDING PAYMENT AGREEMENT AND THE MEMBERSHIP TRANSFER AGREEMENTS; AND (2) BREACH OF GEM LISTING RULES. Source
- Mergers
Transaction under the Listing Rules: DELAY IN DESPATCH OF CIRCULAR AND GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 19.41(a) OF THE GEM LISTING RULES. Source
- Mergers
Transaction under the Listing Rules: DELAY IN DESPATCH OF CIRCULAR REGARDING (1) MAJOR TRANSACTIONS IN RELATION TO THE OUTSTANDING PAYMENT AGREEMENT AND THE MEMBERSHIP TRANSFER AGREEMENTS; AND (2) BREACH OF GEM LISTING RULES. Source
- Mergers
Transaction under the Listing Rules: VOLUNTARY ANNOUNCEMENT FORMAL TERMINATION OF THE DISCLOSEABLE TRANSACTION IN RELATION TO THE SUBSCRIPTION OF INCREASED REGISTERED CAPITAL IN THE TARGET COMPANY. Source
- Mergers
Transaction under the Listing Rules: (1) MAJOR TRANSACTIONS IN RELATION TO THE OUTSTANDING PAYMENT AGREEMENT AND THE MEMBERSHIP TRANSFER AGREEMENTS; AND (2) BREACH OF GEM LISTING RULES. Source
- Financings
Share or debt issue: PROPOSAL FOR (1) GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES; (2) EXTENSION OF GENERAL MANDATE TO ISSUE SHARES; (3) RE-ELECTION OF THE RETIRING DIRECTORS; (4) TERMINATION OF THE EXISTING SHARE OPTION SCHEME AND PROPOSED ADOPTION OF THE NEW SHARE OPTION SCHEME; AND (5) NOTICE OF ANNUAL GENERAL MEETING. Source
- Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION IN RESPECT OF THE TENANCY AGREEMENT OF THE PREMISES. Source
Press releases
- HKEXnews
- HKEXnews
Letter to Non-registered Shareholder - New Arrangements on Dissemination of Corporate Communications
- HKEXnews
- HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
- HKEXnews
- HKEXnews
- HKEXnews
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION
- HKEXnews
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
Stock chart
Listing details
- Company
- China Regenerative Medicine International Limited
- Ticker
- 8158
- Listing
- HKEX
- Country or territory
- Hong Kong
- Business scope
- Pharmaceuticals: Major
- ISIN
- KYG2129W1380
- Last quote in directory
- 2026-10-22
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction